Overview

A Study to Evaluate IBI112 in the Treatment of Psoriasis With Moderate to Severe Plaque Psoriasis

Status:
Recruiting
Trial end date:
2023-01-31
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the efficacy and safety of IBI112 administered in different dose regimens for the treatment of patients with plaque psoriasis
Phase:
Phase 2
Details
Lead Sponsor:
Innovent Biologics (Suzhou) Co. Ltd.